Pain accounted for a 45.8% share of the global clinical trials within the Central Nervous System therapy area in 2021, registering a decrease of 1.1% when compared with the last ten-year average of 46.9% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Non-industry sponsored trials outnumber industry sponsored trials for Pain
Industry sponsored trials held a 20.6% share of all the clinical trials for Pain indication in 2021, registering a decrease of 0.2% when compared with the ten-year average of 20.8%. Non-industry sponsored trials accounted for a 79.4% share in 2021, registering an increase of 0.2% over the ten-year average of 79.2%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top regions of industry sponsored Pain trials
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAsia-Pacific was the top region for industry sponsored Pain trials, accounting for a 55.7% share in 2021, when compared with the five-year average of 43.6% and ten-year average of 35.8%.
Europe was at the second position with a 26.2% share in 2021, over the five-year average of 25.4% and ten-year average of 29.8%, followed by North America with a 22.6% share in 2021, as against five-year and ten-year averages of 35.3% and 39.7% respectively.
Middle East and Africa stood fourth with a 3.4% share in 2021, compared with the five-year average of 3.9% and ten-year average of 3.7%, followed by South and Central America with a 2.7% share in 2021, over five-year and ten-year averages of 2.3% and 2.5% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for industry sponsored Pain trials, accounting for a 34.4% share in 2021, as against the five-year average of 17.8% and ten-year average of 10.0%.
The US held a 20.8% share in 2021, over the five-year average of 33.0% and ten-year average of 37.1%, followed by Russia with a 13.1% share in 2021, compared with the five-year and ten-year averages of 6.9% and 7.8% respectively.
India held a 7.5% share in 2021, as against the five-year average of 7.2% and ten-year average of 6.9%.
Australia held a 5.4% share in 2021, over the five-year and ten-year averages of 5.7% and 5.6% respectively.
Top regions of non-industry sponsored Pain trials
Asia-Pacific was the top region for non-industry sponsored Pain trials, accounting for a 45.7% share in 2021 when compared with the five-year average of 40.8% and ten-year average of 35.2%.
Middle East and Africa was at the second position with a 21.8% share in 2021, over the five-year and ten-year averages of 24.5% and 24.3% respectively, followed by Europe with a 16.2% share in 2021, as against the five-year average of 17.0% and ten-year average of 19.9%.
North America stood at the fourth position with a 14.9% share in 2021, compared with the five-year average of 16.0% and ten-year average of 18.6%, followed by South and Central America with a 1.4% share in 2021, over the five-year and ten-year averages of 2.1% and 2.4% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for non-industry sponsored Pain trials, accounting for a 22.7% share in 2021, as against the five-year average of 13.7% and ten-year average of 9.8%.
The US held a 13.0% share in 2021, over the five-year average of 13.5% and ten-year average of 15.6%, followed by India with an 11.7% share, compared with the five-year and ten-year averages of 14.5% and 11.1% respectively.
Iran held a 10.2% share in 2021, as against the five-year average of 13.5% and ten-year average of 15.9%.
Egypt held a 9.8% share in 2021, over the five-year average of 8.7% and ten-year average of 5.8%.
Phase I trials lead industry sponsored clinical trials for Pain in 2021
Phase I trials held a 50.4% share of industry sponsored clinical trials for Pain in 2021, over the five-year average of 38.3% and ten-year average of 36.5%.
Phase II trials held a 21.3% share in 2021, as against the five-year average of 27.8% and ten-year average of 26.8%. Phase III trials held a 17.4% share in 2021, compared with the five-year and ten-year averages of 21.7% and 23.3% respectively.
Phase IV trials held a 10.9% share in 2021, over the five-year average of 12.2% and ten-year average of 13.4%.
Phase II trials lead non-industry sponsored clinical trials for Pain in 2021
Phase II trials held a 41.8% share of non-industry sponsored clinical trials for Pain in 2021, over the five-year average of 51.6% and ten-year average of 51.6%.
Phase IV trials held a 27.5% share in 2021, as against the five-year average of 24.6% and ten-year average of 26.9%. Phase III trials held a 17.4% share, compared with the five-year and ten-year averages of 16.5% and 15.8% respectively.
Phase I trials held a 13.3% share in 2021, over the five-year average of 7.2% and ten-year average of 5.7%.
Methodology: The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
